/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

IN8BIO, INC

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$1.75 -0.0169(-1.69%) INAB at 04 Dec 2025 04:35 PM Biotechnology
Lowest Today 1.74
Highest Today 1.8
Today’s Open 1.795
Prev. Close 1.78
52 Week High 12.54
52 Week Low 1.53
Day’s Range: Low 1.74 High 1.8
52-Week Range: Low 1.53 High 12.54
1 day return -
1 Week return -14.21
1 month return +4.16
3 month return -19.72
6 month return -52.91
1 year return +483.13
3 year return -28.86
5 year return -
10 year return -

Institutional Holdings

BIOS CAPITAL MANAGEMENT, LP 6.31

Franklin Resources Inc 4.18

AIGH Capital Management, LLC 3.30

Franklin Biotechnology Discv A(acc)USD 2.65

Alyeska Investment Group, L.P. 1.82

Stonepine Capital Management Llc 1.82

Franklin Biotechnology Discovery A 1.53

Vanguard Group Inc 1.32

Vanguard Total Stock Mkt Idx Inv 0.68

Vanguard Institutional Extnd Mkt Idx Tr 0.43

Geode Capital Management, LLC 0.41

Fidelity Extended Market Index 0.23

Northwestern Mutual Wealth Management Co 0.07

Fidelity Series Total Market Index 0.06

Spartan Extended Market Index Pool F 0.05

Northern Trust Extended Eq Market Idx 0.05

NT Ext Equity Mkt Idx Fd - L 0.05

Fidelity Total Market Index 0.04

Tower Research Capital LLC 0.03

Spartan Total Market Index Pool G 0.02

NT Ext Equity Mkt Idx Fd - NL 0.02

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.02

NT Ext Eq Mkt Indx Fd DC Lending Tier 5 0.01

Fidelity Nasdaq Composite Index 0.01

NT Ext Eq Mkt Indx Fd DC Lend T3 0.01

UBS Group AG 0.01

State St US Extended Mkt Indx NL Cl C 0.01

BlackRock Inc 0.00

Northern Trust Wilshire 5000 0.00

Bank of America Corp 0.00

Fidelity U.S. Equity Index Ins Trust 0.00

683 Capital Management LLC 0.00

Citadel Advisors Llc 0.00

Goldman Sachs Group Inc 0.00

Jane Street Group LLC 0.00

Northern Trust Corp 0.00

Sigma Planning Corp 0.00

State Street Corp 0.00

Susquehanna International Group, LLP 0.00

Market Status

Strong Buy: 2

Buy: 2

Hold: 0

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 8.25 M

PB Ratio 0.6957

PE Ratio 0.0

Enterprise Value 1.44 M

Total Assets 20.94 M

Volume 20426

Company Financials

Annual Revenue FY23:0 0.0M, FY22:0 0.0M, FY21:0 0.0M, FY20:0 0.0M, FY19:0 0.0M

Annual Profit FY23:-2501000 -2.5M, FY22:null 0.0M, FY21:null 0.0M, FY20:null 0.0M, FY19:null 0.0M

Annual Net worth FY23:-30007000 -30.0M, FY22:-27418000 -27.4M, FY21:-14653000 -14.7M, FY20:-8557000 -8.6M, FY19:-5134000 -5.1M

Quarterly Revenue Q3/2025:0 0.0M, Q2/2025:0 0.0M, Q1/2025:0 0.0M, Q3/2024:0 0.0M, Q2/2024:0 0.0M

Quarterly Profit Q3/2025:null 0.0M, Q2/2025:-498000 -0.5M, Q1/2025:-429000 -0.4M, Q3/2024:null 0.0M, Q2/2024:-631000 -0.6M

Quarterly Net worth Q3/2025:-3854000 -3.9M, Q2/2025:-5094000 -5.1M, Q1/2025:-5550000 -5.6M, Q3/2024:-7086000 -7.1M, Q2/2024:-8629000 -8.6M

Fund house & investment objective

Company Information IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its products include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation. The company also develops INB-619, a gamma-delta TCE targeting CD19 for both oncology and autoimmune diseases; INB-300, a nsCAR-enabled DeltEx product candidates targeting difficult liquid tumors and extracranial solid tumors; and INB-500, an induced pluripotent stem cell derived gamma-delta T cells that are in preclinical phase for treatment of cancer. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is based in New York, New York.

Organisation Biotechnology

Employees 17

Industry Biotechnology

CEO Mr. Tai-Wei Ho

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow